|Bid||293.51 x 1000|
|Ask||0.00 x 1100|
|Day's range||275.03 - 286.80|
|52-week range||75.35 - 464.00|
|Beta (5Y monthly)||-1.16|
|PE ratio (TTM)||15.91|
|Earnings date||09 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||327.99|
BioNTech (NASDAQ: BNTX) was up by 15.6% for the week as of the market close on Thursday, according to data from S&P Global Market Intelligence. Shares of Novavax (NASDAQ: NVAX), meanwhile, have lost 14.3%. BioNTech benefited from two positive developments.
What happened Shares of BioNTech (NASDAQ: BNTX) were jumping 5.5% higher as of 3:05 p.m. EDT on Thursday. The gain came after the company and its big partner, Pfizer (NYSE: PFE), announced efficacy of 95.
NEW YORK & MAINZ, Germany, October 21, 2021--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine in more than 10,000 individuals 16 years of age and older. In the trial, a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series restored vaccine protection against COVID